炭疽疫苗市場- 按類型（無細胞PA 疫苗[吸收、沉澱]、減毒活疫苗）、應用（人類使用、獸醫使用）、最終用途（獸醫醫院和診所、醫院和診所）和預測（2024 年- 2032 年） ）

在疫苗生產投資增加的推動下，2024年至2032年全球炭疽疫苗市場複合年成長率將達到5.4%。各國政府和私部門利害關係人正在認知到，迫切需要有效接種炭疽疫苗，炭疽是一種嚴重的細菌感染，可用作生物恐怖主義武器。因此，大量資金被用於先進的炭疽疫苗研究、開發和製造。

例如，2024 年 1 月，美國國防部 (DoD) 授予 Emergent BioSolutions 一份價值高達 2.358 億美元的採購契約，用於無限期交付和無限數量 (IDIQ) 供應 BioThrax。根據這份契約，Emergent 將向所有面臨炭疽暴露高風險的美國軍事人員提供 BioThrax。

不斷增強的公共衛生意識和政府措施正在推動市場成長。投資不僅可以提高疫苗的可用性，還可以確保生產技術的改進、功效的提高和可及性的提高。此外，COVID-19 大流行凸顯了強大的疫苗基礎設施的重要性，促使人們進一步投資於能夠生產各種疫苗（包括炭疽疫苗）的設施。因此，在旨在保障公眾健康和國家安全的財政承諾的支持下，炭疽疫苗市場可望大幅成長。

炭疽疫苗產業的整體價值根據類型、應用、最終用途和地區進行分類。

2024 年至 2032 年，來自減毒活疫苗領域的炭疽疫苗市場收入將實現令人稱讚的複合年成長率。它們的功效和誘導強大免疫反應的能力使它們備受追捧，特別是在炭疽暴露風險高的地區。對生物技術和先進疫苗生產技術的投資進一步提振了市場。減毒活疫苗為軍事人員、農業工人和流行地區人群提供了可靠的解決方案，推動了炭疽疫苗市場的大幅成長。

從 2024 年到 2032 年，人類使用部分將顯著成長。疫苗技術的進步和公眾健康意識的提高導致對研究和生產的投資增加。此外，各國監管部門的批准和戰略儲備措施正在提振市場需求。因此，人用炭疽疫苗市場正在經歷顯著成長，確保做好準備並保障公眾健康。

2024年至2032年，歐洲炭疽疫苗市場將呈現顯著的複合年成長率。歐盟對疫苗研發的監管支持和資助正在進一步推動市場成長。此外，生物技術公司和公共衛生機構之間的合作正在提高疫苗的可用性和功效。這種積極主動的做法確保歐洲做好充分準備，減輕炭疽疫情的風險，進而推動炭疽疫苗市場的持續需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 全球炭疽病負擔日益加重
    • 疫苗研發的技術進步
    • 全球化與旅行的增加
  • 產業陷阱與挑戰
    • 缺乏對目標疾病診斷測試的認知
    • 疫苗成本高
• 成長潛力分析
• 監管環境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

• 主要趨勢
• 無細胞PA疫苗
  • 炭疽疫苗吸收（AVA）
  • 炭疽疫苗沉澱 (AVP)
• 減毒活疫苗

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 獸醫用途
• 人類使用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 獸醫醫院和診所
• 醫院及診所
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Altimmune Inc.
• Agrovet
• Bayer AG
• Bavarian Nordic
• Biogenesis Bago SA
• Ceva Sante Animale
• Colondo Serum Company
• Emergent BioSolutions
• Elusys Therapeutics Inc.
• Indian Immunologicals Ltd.
• Intervac (PVT) Ltd
• JOVAC
• Merck Co, Inc.
• Proton Biopharma Ltd.

Global Anthrax Vaccine Market will witness 5.4% CAGR between 2024 and 2032, driven by increasing investments in vaccine production. Governments and private sector stakeholders are recognizing the critical need for effective vaccination against anthrax, a serious bacterial infection that can be used as a bioterrorism weapon. Consequently, significant funds are being directed towards research, development, and manufacturing of advanced anthrax vaccines.

For instance, in January 2024, The US Department of Defense (DoD) awarded Emergent BioSolutions a procurement contract valued at up to $235.8 million for an indefinite-delivery and indefinite-quantity (IDIQ) supply of BioThrax. Under this contract, Emergent will provide BioThrax to all US military personnel at high risk of anthrax exposure.

The growing public health awareness and government initiatives are fueling market growth. Investments are not only enhancing vaccine availability but also ensuring improved production techniques, higher efficacy, and greater accessibility. Additionally, the COVID-19 pandemic has underscored the importance of robust vaccine infrastructure, prompting further investments into facilities capable of producing a wide range of vaccines, including those for anthrax. As a result, the anthrax vaccine market is poised for substantial growth, underpinned by financial commitments aimed at safeguarding public health and national security.

The overall Anthrax Vaccine Industry value is classified based on the type, application, end-use, and region.

The anthrax vaccine market revenue from the live attenuated vaccine segment will register a commendable CAGR from 2024 to 2032. These vaccines, which contain a weakened form of the bacterium that causes anthrax, provide strong and long-lasting immunity. Their efficacy and ability to induce a robust immune response make them highly sought after, particularly in regions with high anthrax exposure risks. Investments in biotechnology and advanced vaccine production techniques have further bolstered the market. Live attenuated vaccines offer a reliable solution for military personnel, agricultural workers, and populations in endemic areas, driving substantial growth in the anthrax vaccine market.

The human use segment will witness an appreciable growth from 2024 to 2032. Governments and health organizations are prioritizing the vaccination of high-risk groups, such as military personnel and laboratory workers. Advances in vaccine technology and heightened public health awareness have led to increased investments in research and production. Furthermore, regulatory approvals and strategic stockpiling initiatives by various countries are bolstering market demand. As a result, the anthrax vaccine market for human use is experiencing significant growth, ensuring preparedness and safeguarding public health.

Europe anthrax vaccine market will exhibit a notable CAGR from 2024 to 2032. European governments are investing in advanced vaccine production and stockpiling to protect high-risk populations, such as military personnel and emergency responders. The European Union's regulatory support and funding for vaccine research and development are further propelling market growth. Additionally, collaborations between biotech companies and public health institutions are enhancing vaccine availability and efficacy. This proactive approach ensures Europe is well-prepared to mitigate the risks of anthrax outbreaks, driving sustained demand in the anthrax vaccine market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing burden of anthrax globally
    • 3.2.1.2 Technology advancements in the vaccine development
    • 3.2.1.3 Increased globalization and travel
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of awareness for diagnostic test of target disease
    • 3.2.2.2 High cost of vaccine
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cell free PA vaccine
  • 5.2.1 Anthrax vaccine absorbed (AVA)
  • 5.2.2 Anthrax vaccine precipitated (AVP)
• 5.3 Live attenuated vaccine

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Veterinary use
• 6.3 Human use

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Veterinary hospitals & clinics
• 7.3 Hospital & clinics
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Altimmune Inc.
• 9.2 Agrovet
• 9.3 Bayer AG
• 9.4 Bavarian Nordic
• 9.5 Biogenesis Bago SA
• 9.6 Ceva Sante Animale
• 9.7 Colondo Serum Company
• 9.8 Emergent BioSolutions
• 9.9 Elusys Therapeutics Inc.
• 9.10 Indian Immunologicals Ltd.
• 9.11 Intervac (PVT) Ltd
• 9.12 JOVAC
• 9.13 Merck Co, Inc.
• 9.14 Proton Biopharma Ltd.